Cilomilast is a synthetic drug developed for the treatment of chronic obstructive pulmonary disease (COPD). It is a phosphodiesterase 4 (PDE4) inhibitor, which is an enzyme involved in the regulation of inflammatory responses in the body. Cilomilast is an orally administered compound that is currently being used as an alternative to other COPD medications. The chemical name of Cilomilast is 3-(Cyclopentyloxy)-4-methoxybenzaldehyde-8-methyl-2-oxo-2H-chromene-7-carboxylic acid. The molecular formula of cilomilast is C20H19NO6 and the formula weight is 369.37 g/mol. It has a CAS number of 153259-65-5.
Top ten keywords associated with Cilomilast as found on Google are:
Common synonyms for Cilomilast include SB-207,499 and SB-207,499-A.
Cilomilast works by inhibiting the activity of phosphodiesterase 4 (PDE4), an enzyme that breaks down cyclic adenosine monophosphate (cAMP). By increasing the level of cAMP in the body, cilomilast can reduce inflammation and promote relaxation of the airways, making it easier to breathe. This mechanism of action makes cilomilast particularly effective in the treatment of respiratory conditions such as COPD.
One of the primary health benefits of cilomilast is its ability to improve lung function and reduce the severity of symptoms associated with COPD. This includes improving breathing capacity, reducing shortness of breath, and decreasing the frequency of wheezing and coughing. Additionally, cilomilast has shown promise in the treatment of other respiratory conditions, such as asthma and bronchitis.
While cilomilast can be an effective treatment option for respiratory conditions, there are also potential side effects associated with its use. Some of the more common side effects include nausea, vomiting, diarrhea, and headache. More serious side effects are rare, but can include liver damage and allergic reactions.
Dosage information for cilomilast typically involves taking one 15mg tablet twice a day. However, the exact dosage and administration may vary depending on the individual patient and the severity of their condition. It is important to follow the instructions provided by a healthcare professional and not to exceed the recommended dosage.
Overall, cilomilast is a promising new drug that shows great potential in the treatment of respiratory conditions such as COPD. Its mechanism of action is unique and effective, and it has been shown to improve lung function and reduce symptoms in patients. While there are some potential side effects and safety concerns associated with its use, the benefits of cilomilast make it a valuable addition to the arsenal of treatments available for respiratory conditions. As always, it is important to consult with a healthcare professional before starting any new medication.
